CN102203085A - 用于制备苹果酸舒尼替尼晶体形式的新方法 - Google Patents

用于制备苹果酸舒尼替尼晶体形式的新方法 Download PDF

Info

Publication number
CN102203085A
CN102203085A CN2009801339602A CN200980133960A CN102203085A CN 102203085 A CN102203085 A CN 102203085A CN 2009801339602 A CN2009801339602 A CN 2009801339602A CN 200980133960 A CN200980133960 A CN 200980133960A CN 102203085 A CN102203085 A CN 102203085A
Authority
CN
China
Prior art keywords
malic acid
sunitinib
solvent
mixture
sutent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801339602A
Other languages
English (en)
Chinese (zh)
Inventor
阿沛·盖顿德
维纳亚克·戈雷
巴拉蒂·乔杜里
马赫什·胡布利卡
普拉卡什·班索德
苏纳达·菲德塔尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Generics UK Ltd
Original Assignee
Generics UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Generics UK Ltd filed Critical Generics UK Ltd
Publication of CN102203085A publication Critical patent/CN102203085A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN2009801339602A 2008-07-10 2009-07-09 用于制备苹果酸舒尼替尼晶体形式的新方法 Pending CN102203085A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN1193/KOL/2008 2008-07-10
IN1193KO2008 2008-07-10
PCT/GB2009/050818 WO2010004339A1 (en) 2008-07-10 2009-07-09 Processes for the preparation of crystalline forms of sunitinib malate

Publications (1)

Publication Number Publication Date
CN102203085A true CN102203085A (zh) 2011-09-28

Family

ID=41100787

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801339602A Pending CN102203085A (zh) 2008-07-10 2009-07-09 用于制备苹果酸舒尼替尼晶体形式的新方法

Country Status (7)

Country Link
US (1) US20110257237A1 (https=)
EP (1) EP2297138A1 (https=)
JP (1) JP2011527330A (https=)
CN (1) CN102203085A (https=)
AU (1) AU2009269768A1 (https=)
CA (1) CA2730079A1 (https=)
WO (1) WO2010004339A1 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104114550A (zh) * 2012-03-23 2014-10-22 劳拉斯实验室私人有限公司 制备舒尼替尼及其酸加成盐的改进的方法
CN104693187A (zh) * 2013-12-10 2015-06-10 安杰世纪生物科技（北京）有限公司 一种舒尼替尼L-苹果酸盐晶型λ及其制备方法
CN105085490A (zh) * 2014-05-09 2015-11-25 上海科胜药物研发有限公司 新的舒尼替尼苹果酸盐晶型及其制备方法
CN115057814A (zh) * 2021-12-07 2022-09-16 山东新时代药业有限公司 一种米力农苹果酸盐晶体

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102197035A (zh) * 2008-08-25 2011-09-21 基因里克斯(英国)有限公司 舒尼替尼的结晶形式及其制备方法
EP2499133A2 (en) * 2009-11-12 2012-09-19 Ranbaxy Laboratories Limited Process for the preparation of crystalline form i of l-malic acid salt of sunitinib
WO2011092664A1 (en) 2010-01-29 2011-08-04 Ranbaxy Laboratories Limited Crystalline forms of l-malic acid salt of sunitinib
CA2838587A1 (en) * 2013-10-18 2015-04-18 Hari Babu Matta Pure crystalline form ii of l-malic acid salt of sunitinib and processes for its preparation

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001060814A2 (en) * 2000-02-15 2001-08-23 Sugen, Inc. Pyrrole substituted 2-indolinone protein kinase inhibitors
CN1543462A (zh) * 2001-08-15 2004-11-03 �������Ŷ���Լ��������˾ 包括n－[2－(二乙氨基)乙基]－5－[(5－氟－2－氧代－3h－吲哚－3－亚基)甲基]－2,4－二甲基－1h－吡咯－3－甲酰胺的苹果酸盐的晶体、其制备方法和其组合物
CN1758914A (zh) * 2003-02-24 2006-04-12 苏根公司 用吲哚啉酮化合物治疗过度骨质溶解
WO2009067686A2 (en) * 2007-11-21 2009-05-28 Teva Pharmaceutical Industries Ltd. Sunitinib hemi-l-malate, polymorphs and preparation thereof, polymorphs of racemic sunitinib malate, compositins containing sunitinib base and malic acid and preparation thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040209937A1 (en) * 2003-02-24 2004-10-21 Sugen, Inc. Treatment of excessive osteolysis with indolinone compounds

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001060814A2 (en) * 2000-02-15 2001-08-23 Sugen, Inc. Pyrrole substituted 2-indolinone protein kinase inhibitors
CN1543462A (zh) * 2001-08-15 2004-11-03 �������Ŷ���Լ��������˾ 包括n－[2－(二乙氨基)乙基]－5－[(5－氟－2－氧代－3h－吲哚－3－亚基)甲基]－2,4－二甲基－1h－吡咯－3－甲酰胺的苹果酸盐的晶体、其制备方法和其组合物
CN1758914A (zh) * 2003-02-24 2006-04-12 苏根公司 用吲哚啉酮化合物治疗过度骨质溶解
WO2009067686A2 (en) * 2007-11-21 2009-05-28 Teva Pharmaceutical Industries Ltd. Sunitinib hemi-l-malate, polymorphs and preparation thereof, polymorphs of racemic sunitinib malate, compositins containing sunitinib base and malic acid and preparation thereof

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104114550A (zh) * 2012-03-23 2014-10-22 劳拉斯实验室私人有限公司 制备舒尼替尼及其酸加成盐的改进的方法
CN104693187A (zh) * 2013-12-10 2015-06-10 安杰世纪生物科技（北京）有限公司 一种舒尼替尼L-苹果酸盐晶型λ及其制备方法
CN105085490A (zh) * 2014-05-09 2015-11-25 上海科胜药物研发有限公司 新的舒尼替尼苹果酸盐晶型及其制备方法
CN115057814A (zh) * 2021-12-07 2022-09-16 山东新时代药业有限公司 一种米力农苹果酸盐晶体

Also Published As

Publication number Publication date
EP2297138A1 (en) 2011-03-23
US20110257237A1 (en) 2011-10-20
AU2009269768A1 (en) 2010-01-14
CA2730079A1 (en) 2010-01-14
JP2011527330A (ja) 2011-10-27
WO2010004339A1 (en) 2010-01-14

Similar Documents

Publication Publication Date Title
CN102203085A (zh) 用于制备苹果酸舒尼替尼晶体形式的新方法
JP5916752B2 (ja) ５−クロロ−ｎ２−（２−イソプロポキシ−５−メチル−４−ピペリジン−４−イル−フェニル）−ｎ４［２−（プロパン−２−スルホニル）−フェニル］−ピリミジン−２，４−ジアミンの結晶形
JP2011512396A (ja) 新規な多形およびその調製方法
KR20160121544A (ko) N-｛4-[(6,7-다이메톡시퀴놀린-4-일)옥시]페닐｝-n''-(4-플루오로페닐) 사이클로프로판-1,1-다이카복스아마이드의 결정질 고체 형태, 제조 방법 및 사용 방법
KR101604501B1 (ko) Ｎ-[2-(다이에틸아미노)에틸]-5-[(5-플루오로-1,2-다이하이드로-2-옥소-3ｈ-인돌-3-일리덴)메틸]-2,4-다이메틸-1ｈ-피롤-3-카복스아미드의 결정 형태 및 이의 제조 방법
EP2253629A1 (en) Polymorphs of racemic sunitinib malate, compositions containing them and preparation thereof
CN102149384A (zh) 作为ep4受体拮抗剂的杂环酰胺衍生物
JP2010116409A (ja) 高純度カンデサルタンシレキセチルの調製
CN102070618A (zh) 一种化合物及其晶体
CN107827875B (zh) 一种苯并咪唑类衍生物作为周期蛋白依赖性激酶4/6抑制剂的应用
CN104098570A (zh) 替卡格雷晶型及其制备方法和用途
CN102197035A (zh) 舒尼替尼的结晶形式及其制备方法
WO2014194795A1 (zh) 吲哚酮化合物或其衍生物及其用途
TWI765086B (zh) Parp-1抑制劑的晶型及其製備方法
CN103880829B (zh) 一种阿齐沙坦晶体及其制备方法和用途
JP4657393B2 (ja) ドキサゾシン・メシレートの新規な形態ｉｉｉ
CN105566294B (zh) 一种右旋艾普拉唑钠化合物及其药物组合物
TW202043209A (zh) Mek抑制劑及其在醫藥上的應用
JP2018518515A (ja) フェニルアミノピリミジン化合物またはその塩の多形物
JP6072908B2 (ja) 重水素化ω―ジメチル尿素又はその塩の多形物
US20110263670A1 (en) Novel polymorphs of sunitinib and processes for their preparation
CN107235994B (zh) 5,7-二苯基-5H-噻唑并[3,2-a]嘧啶-3-乙酰胺类衍生物及应用
CN114656468B (zh) 酪蛋白激酶1ε抑制剂的晶型、制备方法及其应用
US20210380586A1 (en) 2-indolyl imidazo[4,5-d]phenanthroline polymorphs and compositions regarding the same
WO2025007840A1 (zh) 联嘧啶化合物的晶型及其制备方法和用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20110928